Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
A Multicenter Clinical Study on a New Treatment Model Combining New Surgical Techniques, Perioperative Comprehensive Treatment, and Postoperative Rehabilitation for Elderly Patients With Lung Cancer
Peking University People's Hospital
1,000 participants
Aug 1, 2024
INTERVENTIONAL
Conditions
Summary
This multicenter prospective clinical study focuses on elderly patients with lung cancer. We will build a standardized clinical registry database, develop perioperative risk stratification and surgical early-warning models, optimize individualized surgical regimens, construct multidisciplinary perioperative comprehensive therapy, integrated Chinese-Western medicine full-cycle management and personalized postoperative rehabilitation systems, so as to form a whole-process optimized treatment model for elderly lung cancer.
Eligibility
Inclusion Criteria5
- Aged ≥65 years old
- Pathologically confirmed non-small cell lung cancer with clinical stage eligible for curative surgical resection
- Complete preoperative geriatric comprehensive assessment data available
- Capable of finishing planned surgery and long-term follow-up
- Voluntarily sign informed consent form
Exclusion Criteria6
- History of other malignant tumors within recent 5 years
- Severe organic dysfunction of heart, liver, renal or respiratory system that cannot tolerate thoracic surgery
- Preoperative confirmed distant metastasis preventing radical resection
- Uncontrolled active severe infection or obvious coagulation disorders
- Severe psychiatric disorder or cognitive dysfunction failing to cooperate with treatment and follow-up
- Refuse random grouping and postoperative regular monitoring
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Standard anatomical lobectomy combined with systematic mediastinal lymph node sampling for early-stage T1N0M0 non-small cell lung cancer in patients aged ≥65 years; postoperative stratified adaptive perioperative management guided by MRD and tumor biomarkers.
Curative segmentectomy with mediastinal lymph node sampling after preoperative comprehensive geriatric risk assessment (CGA, VES-13, ASA grading); postoperative personalized perioperative treatment stratified by postoperative minimal residual disease status.
Wedge resection plus mediastinal lymph node sampling for eligible elderly early lung cancer patients; low-risk subjects receive de-escalated adaptive perioperative treatment, while high-risk patients receive intensified comprehensive therapy based on postoperative risk stratification.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07632664